Holen Sie sich die Stockscreener-App
9.58
2.57%
0.24
Handel nachbörslich:
9.73
0.15
+1.57%
Schlusskurs vom Vortag:
$9.34
Offen:
$9.64
24-Stunden-Volumen:
4.31M
Relative Volume:
0.90
Marktkapitalisierung:
$2.43B
Einnahmen:
$885.72M
Nettoeinkommen (Verlust:
$-457.98M
KGV:
-5.3926
EPS:
-1.7765
Netto-Cashflow:
$293.05M
1W Leistung:
+5.16%
1M Leistung:
-3.62%
6M Leistung:
+41.72%
1J Leistung:
+12.05%
1-Tages-Spanne:
$9.58
$9.91
1-Wochen-Bereich:
$9.11
$9.91
52-Wochen-Spanne:
$6.00
$11.22
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.58 | 2.37B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Orbimed Advisors LLC Sells 316,600 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharma Market Sentiment - Benzinga España
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
TradingKey - TradingKey
BioCryst Pharmaceuticals Inc - TradingKey
Rice Hall James & Associates LLC Acquires 325,959 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals, Inc. Revenue Breakdown – MUN:BO1 - TradingView
BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data - Stocktwits
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BCRX Q2'26 Earnings: revenue estimate is 183.28M USD - TradingView
(BCRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals - simplywall.st
BCRX|BioCryst Pharmaceuticals Inc|Price:9.340|Chg%:-0.040 - TradingKey
BioCryst schedules a look at second-quarter results for Aug. 5 - Stock Titan
BioCryst to Report Second Quarter 2026 Financial Results on August 5 - The Manila Times
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story? - Sahm
BioCryst Pharmaceuticals (BCRX): Investor Outlook on a Biotech with 130% Potential Upside - DirectorsTalk Interviews
BioCryst Pharmaceuticals (BCRX) Proxy filing Summary - Quartr
BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary - Quartr
Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook By Investing.com - Investing.com Nigeria
BioCryst stock trades steadily as Orladeyo revenue supports rare disease focus - ad-hoc-news.de
Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook - Investing.com
BioCryst Appoints David W. Jenkins as Chief Scientific Officer - Sahm
631,290 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by IMC Chicago LLC - MarketBeat
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $15 - Moomoo
BioCryst Pharmaceuticals Names David W. Jenkins Chief Scientific Officer to Lead External Innovation Strategy - Quiver Quantitative
BioCryst names David Jenkins as chief scientific officer By Investing.com - Investing.com Canada
BioCryst’s New Science Chief Brings Over 20 Years in Biopharma - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet - Zacks Investment Research
BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure - Sahm
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits
BCRX Reinstated by JP Morgan -- Price Target Announced at $12.00 - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus - Sahm
BioCryst (BCRX) Coverage Resumed by JPMorgan with Neutral Rating - GuruFocus
JPMorgan resumes BioCryst Pharma stock coverage with neutral rating - Investing.com
JPMorgan resumes BioCryst Pharma stock coverage with neutral rating By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 Summary - Quartr
Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model? - Sahm
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility - Yahoo Finance
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):